top of page
GU cancers
Neoadjuvant MVAC | 2003 | Bladder - advanced |
BC2001 trial, RT w/wo chemo | 2012 | Bladder - advanced |
Keynote 045 | 2017 | Bladder - advanced |
Checkmate 275 | 2017 | Bladder - advanced |
Erdafitinib trial | 2019 | Bladder - advanced |
JAVELIN Bladder 100 Trial | 2020 | Bladder - advanced |
Keynote 052 | 2020 | Bladder - advanced |
EV 301 trial (Enfortumab Vedotin) | 2021 | Bladder - advanced |
Intermittent Androgen suppression | 2012 | Prostate - advanced |
Hero Trial | 2020 | Prostate - advanced |
ENACT Trial, enza vs active surveillance | 2022 | Prostate - early stage |
Docetaxel and Estramustine vs Mitoxantrone | 2004 | Prostate - metastatic |
Affirm Trial | 2012 | Prostate - metastatic |
Prevail Trial | 2014 | Prostate - metastatic |
CHAARTED trial (docetaxel) | 2015 | Prostate - metastatic |
Latitude Trial | 2017 | Prostate - metastatic |
Titan Trial | 2019 | Prostate - metastatic |
Enzamet Trial | 2019 | Prostate - metastatic |
TheraP Trial | 2021 | Prostate - metastatic |
Vision Trial | 2021 | Prostate - metastatic |
ARASENS trial, Docetaxel+ADT +/- Darolutamide | 2022 | Prostate - metastatic |
Sunitinib versus INF-alfa | 2007 | RCC - advanced |
Temsirolimus vs INF-alfa trial | 2007 | RCC - advanced |
IMDC analysis | 2009 | RCC - advanced |
AXIS trial | 2011 | RCC - advanced |
Axitinib dose titration | 2013 | RCC - advanced |
EXIST-2 trial | 2013 | RCC - advanced |
Lenvatinib trial | 2015 | RCC - advanced |
CheckMate 025 trial | 2015 | RCC - advanced |
Surveillance in m-RCC | 2016 | RCC - advanced |
METEOR trial | 2016 | RCC - advanced |
CABOSUN trial | 2017 | RCC - advanced |
IMmotion151 trial | 2019 | RCC - advanced |
CheckMate 214 trial | 2020 | RCC - advanced |
KEYNOTE-426 trial | 2020 | RCC - advanced |
JAVELIN Renal 101 trial | 2020 | RCC - advanced |
CLEAR trial | 2021 | RCC - advanced |
Checkmate 9ER trial | 2021 | RCC - advanced |
ASSURE trial (ECOG-ACRIN E2805) | 2016 | RCC - perioperative |
S-TRAC trial | 2016 | RCC - perioperative |
PROTECT trial | 2017 | RCC - perioperative |
*KEYNOTE-564 trial | 2021 | RCC - perioperative |
**CheckMate 914 trial | 2021 | RCC - perioperative |
CLEAR trial
Motzer R et al, NEJM, 2021; PMID:33616314
RCC - advanced
Background: phase III RCT included 1,069 patients (Fav: 31%, INT 60%, POOR: 9%; ~1/3 had PDL1+score) metastatic RCC
Arm A: Lenvatinib 20mg daily plus pembrolizumab 200mg IV q3w
Arm B: Lenvatinib 18mg PO daily plus everolimus 5mg PO daily
Arm C: Sunitinib 50mg 4wk on, 2wk off
Primary end point: PFS
mFollow up: 26.6mo
mPFS for arm A vs C: 23.9mo vs 9.2mo, HR 0.39, 95%CI 0.32-0.49; P<.001;
mPFS for arm B vs C: 14.7mo vs. 9.2mo, HR 0.65, 95%CI 0.53-0.80, P<.001
mOS for arm A vs C: HR 0.66; 95%CI 0.49-0.88; P=.005
mOS for arm B vs C: HR 1.15; 95%CI 0.88-1.50; P=.30
Conclusions: Lenvatinib and pembrolizumab combination improved mPFS and mOS in patients with metastatic RCC
Summarized by Veli Bakalov, MD
bottom of page